Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.



Latest Headlines

Latest Headlines

GSK signs up to access Metabolon's bioinformatics tools

Metabolon has made a busy start to 2014, with media reports of a planned IPO following news of its partnership with J. Craig Venter's Human Longevity. Now, GlaxoSmithKline has signed up to use Metabolon's bioinformatics and visualization tools as part of a deal to source metabolomic profiling services.

GlaxoSmithKline exec blindsided by Chinese bribery charges: Reuters

The GlaxoSmithKline executive charged with masterminding a Chinese bribery network didn't think he'd face those official accusations, Reuters reports. And no wonder: They're the most serious allegations ever leveled against a foreigner for corporate corruption in the country.

China speaks on GSK bribery charges, and the word isn't good

China is coming down hard on GlaxoSmithKline's local operation. After a months-long bribery probe, Chinese police have slapped Glaxo's former country chief--Mark Reilly, a Brit--and two other top Chinese executives with several counts of bribery.

Top GSK exec faces Chinese prison for alleged 'massive bribery network'

China is coming down hard on GlaxoSmithKline's local operation. After a months-long bribery probe, Chinese police have charged Glaxo's former country chief and two other top execs with several counts of bribery. All could face life in prison.

Chinese officials to shed some light on Glaxo probe at press briefing

What lies ahead for GlaxoSmithKline in China? The company has been waiting to find out since last summer, when investigators there charged it in a massive bribery scheme. But Glaxo may finally get some answers Wednesday, when Chinese police will brief the media about the drugmaker.

GlaxoSmithKline's blockbuster dreams dashed as darapladib goes 0-for-2 in PhIII

GlaxoSmithKline's last-minute gambit to switch the primary endpoint in its remaining Phase III study of the heart drug darapladib failed to pay off. The pharma giant says that its top cardio prospect flunked the second big trial just as it had the first, leaving the pharma giant staring at a likely writeoff of a one-time megablockbuster hopeful.

Glaxo, Sanofi ready to supply vaccines amid polio emergency

In light of news that polio has once again emerged as a public health emergency, vaccinemakers GlaxoSmithKline and Sanofi are reportedly on watch.

The top R&D spenders in biopharma in 2013

Over the past few years, the bottom-line number on R&D spending among the big 10 pharma companies--about $70 billion--has remained about the same. But behind the steady collective figure lies...

GlaxoSmithKline picks up FDA approval for its latest COPD contender

Adding to its string of respiratory victories, GlaxoSmithKline won an FDA nod for Incruse Ellipta, a once-daily COPD inhaler.

GlaxoSmithKline ups odds on heart drug hopeful with a changeup in endpoints

Expecting to improve its odds of success for the experimental heart drug darapladib, a top drug prospect that failed its first late-stage test, investigators at GlaxoSmithKline have changed up the primary endpoint in the remaining Phase III study that reads out later this quarter.